Trial Profile
The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Levetiracetam (Primary) ; Levetiracetam; Temozolomide
- Indications Glioblastoma
- Focus Proof of concept; Therapeutic Use
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Status changed from not yet recruiting to active, no longer recruiting, as reported in an abstract presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 08 Jul 2016 New trial record